ALK and lung cancer: Although crizotinib shows moderate activity against brain metastases in TKI‐naïve ALK‐fusion‐positive lung cancers, a recurrence in CNS lesions is frequently observed at the acquisition of resistance 42, indicating the lower efficacy of crizotinib against brain metastases, compared to its efficacy against extracranial tumor lesions.